HRP20221152T1 - Spojevi korisni u inhibiranju cdk7 - Google Patents
Spojevi korisni u inhibiranju cdk7 Download PDFInfo
- Publication number
- HRP20221152T1 HRP20221152T1 HRP20221152TT HRP20221152T HRP20221152T1 HR P20221152 T1 HRP20221152 T1 HR P20221152T1 HR P20221152T T HRP20221152T T HR P20221152TT HR P20221152 T HRP20221152 T HR P20221152T HR P20221152 T1 HRP20221152 T1 HR P20221152T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- salt
- cancer
- patient
- use according
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 27
- 101150059448 cdk7 gene Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 27
- 230000000415 inactivating effect Effects 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000000523 sample Substances 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- -1 [(3S)-1-[(E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl]-4-[ (3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino]piperidine-1-carboxylate-besylate Chemical compound 0.000 claims 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 238000001712 DNA sequencing Methods 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010073073 Hepatobiliary cancer Diseases 0.000 claims 1
- 102100027755 Histone-lysine N-methyltransferase 2C Human genes 0.000 claims 1
- 102100027768 Histone-lysine N-methyltransferase 2D Human genes 0.000 claims 1
- 101100435489 Homo sapiens ARID1A gene Proteins 0.000 claims 1
- 101000924266 Homo sapiens AT-rich interactive domain-containing protein 1A Proteins 0.000 claims 1
- 101001008892 Homo sapiens Histone-lysine N-methyltransferase 2C Proteins 0.000 claims 1
- 101001008894 Homo sapiens Histone-lysine N-methyltransferase 2D Proteins 0.000 claims 1
- 101100398307 Homo sapiens KMT2C gene Proteins 0.000 claims 1
- 101100398309 Homo sapiens KMT2D gene Proteins 0.000 claims 1
- 101000742859 Homo sapiens Retinoblastoma-associated protein Proteins 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 101150032040 KMT2D gene Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 101150002130 Rb1 gene Proteins 0.000 claims 1
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000012268 genome sequencing Methods 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (24)
1. Spoj, naznačen time što ima formulu (I)
[image]
,
ili njegova farmaceutski prihvatljiva sol.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ima formulu (II)
[image]
,
ili njegova farmaceutski prihvatljiva sol.
3. Spoj u skladu s patentnim zahtjevom 2, naznačen time što ima formulu (II)
[image]
.
4. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ima formulu (III)
[image]
,
ili njegova farmaceutski prihvatljiva sol.
5. Spoj u skladu s patentnim zahtjevom 4, naznačen time što ima formulu (III)
[image]
.
6. Spoj, ili sol, u skladu s patentnim zahtjevom 2, naznačen time što je hidrat hidrokloridne, besilatne ili hemiedisilatne soli.
7. Spoj, ili sol, u skladu s patentnim zahtjevom 4, naznačen time što je hidrat besilatne ili hemiedisilatne soli.
8. Spoj, ili sol, u skladu s patentnim zahtjevom 2, naznačen time što je u obliku kristalne soli.
9. Spoj, ili sol, u skladu s patentnim zahtjevom 8, koji je kristalni [(3S)-1-[(E)-4-(dimetilamino)but-2-enoil]pirolidin-3-il]-4-[(3-izopropil-5-metilpirazolo[1,5-a]pirimidin-7-il)amino]piperidin-1-karboksilat-besilat, naznačen time što ima uzorak difrakcije rendgenskih zraka na prahu koji ima karakteristične vrhove uz pomoć CuKα zračenja, u 2θ ± 0,2°, koji se pojavljuje na 21,5° u kombinaciji s jednim ili više vrhova koje se bira iz skupine kou čine 12,4°, 17,3°, te 15,8°.
10. Spoj, ili sol, u skladu s patentnim zahtjevom 8, koji je [(3S)-1-[(E)-4-(dimetilamino)but-2-enoil]pirolidin-3-il]-4-[(3-izopropil-5-metilpirazolo[1,5-a]pirimidin-7-il)amino]piperidin-1-karboksilat-hemiedisilat hidrat, naznačen time što ima uzorak difrakcije rendgenskih zraka na prahu koji ima karakteristične vrhove uz pomoć CuKα zračenja, u 2θ ± 0,2°, koji se pojavljuje na 18,5° u kombinaciji s jednim ili više vrhova koje se bira iz skupine kou čine 21,5°, 16,7°, te 15,2°.
11. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 10, ili njegovu farmaceutski prihvatljivu sol, u kombinaciji s jednim ili više farmaceutski prihvatljivih nosača, razrjeđivača ili pomoćnih sredstava.
12. Farmaceutski pripravak u skladu s patentnim zahtjevom 11, naznačen time što sadrži jedno ili više drugih terapijskih sredstava.
13. Spoj, ili njegova sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što je namijenjen upotrebi u terapiji.
14. Spoj ili njegova sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što je namijenjen upotrebi u postupku liječenja urotelijalnog raka, raka maternice, kolorektalnog raka, raka dojke, raka pluća, raka jajnika, raka želuca, hepatobilijarnog raka, raka gušterače, rakova vrata maternice, raka prostate, hematoloških rakova, sarkoma, rakova kože ili glioma.
15. Spoj, ili sol, namijenjen upotrebi u skladu s patentnim zahtjevom 14, naznačen time što je rak kolorektalni rak, rak dojke, rak pluća, rak jajnika ili rak želuca.
16. Spoj, ili sol, namijenjen upotrebi u skladu s bilo patentnim zahtjevom 14 ili 15, naznačen time što je rak rak dojke.
17. Spoj, ili njegova sol, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 13 do 16, naznačen time što postupak također uključuje provođenje analize in vitro na biološkom uzorku iz pacijenta, koji se sastoji u određivanju prisutnosti najmanje jedne inaktivirajuće mutacije u genima ARID1A, KMT2C, KMT2D i RB1, te u primjeni terapijske djelotvorne količine spoja, ili njegove soli, na pacijentu ako je prisutna najmanje jedna inaktivirajuća mutacija u bilo kojem od gena.
18. Spoj, ili njegova sol, namijenjen upotrebi u skladu s patentnim zahtjevom 17, naznačen time što je biološki uzorak uzorak tumora, a uzorak se analizira sekvencioniranjem genoma/DNA.
19. Spoj, ili njegova sol, namijenjen upotrebi u skladu s bilo patentnih zahtjeva 17 ili 18, naznačen time što se uzorak dobiva iz pacijenta prije prve primjene spoja, ili njegove soli, na pacijentu.
20. Spoj, ili njegova sol, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 13 do 19, naznačen time što se pacijenta bira za liječenje zbog toga što ima najmanje jednu inaktivirajuću mutaciju u genu ARID1A.
21. Spoj, ili njegova sol, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 13 do 19, naznačen time što se pacijenta bira za liječenje zbog toga što ima najmanje jednu inaktivirajuću mutaciju u genu KMT2C.
22. Spoj, ili njegova sol, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 13 do 19, naznačen time što se pacijenta bira za liječenje zbog toga što ima najmanje jednu inaktivirajuću mutaciju u genu KMT2D.
23. Spoj, ili njegova sol, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 13 do 19, naznačen time što se pacijenta bira za liječenje zbog toga što ima najmanje jednu inaktivirajuću mutaciju u genu RB1.
24. Spoj, ili njegova sol, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 13 do 23, naznačen time što se spoj, ili njegovu sol, primjenjuje na pacijentu u dozi od otprilike 1 mg do 2 g.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382778 | 2017-11-16 | ||
| EP18382034 | 2018-01-23 | ||
| EP18382546 | 2018-07-20 | ||
| PCT/US2018/060025 WO2019099298A1 (en) | 2017-11-16 | 2018-11-09 | Compounds useful for inhibiting cdk7 |
| EP18808599.7A EP3710446B1 (en) | 2017-11-16 | 2018-11-09 | Compounds useful for inhibiting cdk7 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221152T1 true HRP20221152T1 (hr) | 2022-11-25 |
Family
ID=64477309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221152TT HRP20221152T1 (hr) | 2017-11-16 | 2018-11-09 | Spojevi korisni u inhibiranju cdk7 |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10472370B2 (hr) |
| EP (1) | EP3710446B1 (hr) |
| JP (1) | JP6633254B2 (hr) |
| KR (1) | KR102450727B1 (hr) |
| CN (1) | CN111344292B (hr) |
| AU (1) | AU2018369508B2 (hr) |
| BR (1) | BR112020008253A2 (hr) |
| CA (1) | CA3080910C (hr) |
| CL (1) | CL2020001218A1 (hr) |
| CR (1) | CR20200184A (hr) |
| DK (1) | DK3710446T3 (hr) |
| DO (1) | DOP2020000102A (hr) |
| EC (1) | ECSP20025899A (hr) |
| ES (1) | ES2925219T3 (hr) |
| HR (1) | HRP20221152T1 (hr) |
| HU (1) | HUE060078T2 (hr) |
| IL (1) | IL274540B (hr) |
| JO (1) | JOP20200122B1 (hr) |
| LT (1) | LT3710446T (hr) |
| MD (1) | MD3710446T2 (hr) |
| MX (1) | MX2020004932A (hr) |
| MY (1) | MY197700A (hr) |
| NZ (1) | NZ763551A (hr) |
| PE (1) | PE20210392A1 (hr) |
| PL (1) | PL3710446T3 (hr) |
| RS (1) | RS63530B1 (hr) |
| SA (1) | SA520411990B1 (hr) |
| SG (1) | SG11202003677UA (hr) |
| SI (1) | SI3710446T1 (hr) |
| TW (1) | TWI703149B (hr) |
| WO (1) | WO2019099298A1 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3805218A1 (en) * | 2014-04-05 | 2021-04-14 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| TWI703149B (zh) * | 2017-11-16 | 2020-09-01 | 美商美國禮來大藥廠 | 用於抑制cdk7之化合物 |
| JP2023501950A (ja) * | 2019-10-29 | 2023-01-20 | サイロス ファーマシューティカルズ， インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤を用いてバイオマーカーにより特定された患者におけるがんを処置する方法 |
| JP2023507028A (ja) | 2019-12-20 | 2023-02-20 | エボポイント、バイオサイエンシズ、カンパニー、リミテッド | 複素環式化合物とその医薬組成物、調製方法、中間体及び使用 |
| WO2022033552A1 (zh) * | 2020-08-12 | 2022-02-17 | 隆泰申医药科技(南京) 有限公司 | Cdk激酶抑制剂、其制备方法、药物组合物和应用 |
| USD1004118S1 (en) | 2021-08-31 | 2023-11-07 | MerchSource, LLC | Percussion massager |
| USD1004117S1 (en) | 2021-08-31 | 2023-11-07 | MerchSource, LLC | Percussion massager |
| USD1004119S1 (en) | 2021-08-31 | 2023-11-07 | MerchSource, LLC | Percussion massager |
| USD987844S1 (en) | 2021-08-31 | 2023-05-30 | MerchSource, LLC | Percussion massager |
| USD994898S1 (en) | 2021-11-17 | 2023-08-08 | MerchSource, LLC | Percussion massager |
| USD995812S1 (en) | 2021-11-22 | 2023-08-15 | MerchSource, LLC | Percussion massager |
| USD1009292S1 (en) | 2021-12-22 | 2023-12-26 | MerchSource, LLC | Percussion massager |
| USD1018881S1 (en) | 2021-12-22 | 2024-03-19 | MerchSource, LLC | Percussion massager |
| USD1004121S1 (en) | 2021-12-31 | 2023-11-07 | MerchSource, LLC | Pivoting percussion massager |
| USD1004122S1 (en) | 2021-12-31 | 2023-11-07 | MerchSource, LLC | Pivoting percussion massager |
| CN114452391B (zh) * | 2022-01-28 | 2023-08-25 | 深圳市泰尔康生物医药科技有限公司 | Cdk16作为靶标在制备用于治疗三阴性乳腺癌的药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60313872T2 (de) * | 2002-09-04 | 2008-01-17 | Schering Corp. | Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen |
| GB201403093D0 (en) * | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP3805218A1 (en) * | 2014-04-05 | 2021-04-14 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| EP3268000B1 (en) * | 2015-03-09 | 2021-08-04 | Aurigene Discovery Technologies Limited | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors |
| US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| KR20180041112A (ko) | 2015-06-04 | 2018-04-23 | 오리진 디스커버리 테크놀로지스 리미티드 | Cdk 억제제로서의 치환된 헤테로사이클릴 유도체 |
| EP4019515A1 (en) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| TWI703149B (zh) * | 2017-11-16 | 2020-09-01 | 美商美國禮來大藥廠 | 用於抑制cdk7之化合物 |
-
2018
- 2018-10-31 TW TW107138486A patent/TWI703149B/zh active
- 2018-11-09 PL PL18808599.7T patent/PL3710446T3/pl unknown
- 2018-11-09 LT LTEPPCT/US2018/060025T patent/LT3710446T/lt unknown
- 2018-11-09 NZ NZ763551A patent/NZ763551A/en unknown
- 2018-11-09 KR KR1020207013683A patent/KR102450727B1/ko active IP Right Grant
- 2018-11-09 CA CA3080910A patent/CA3080910C/en active Active
- 2018-11-09 BR BR112020008253-8A patent/BR112020008253A2/pt unknown
- 2018-11-09 PE PE2020001000A patent/PE20210392A1/es unknown
- 2018-11-09 HR HRP20221152TT patent/HRP20221152T1/hr unknown
- 2018-11-09 AU AU2018369508A patent/AU2018369508B2/en active Active
- 2018-11-09 MX MX2020004932A patent/MX2020004932A/es unknown
- 2018-11-09 EP EP18808599.7A patent/EP3710446B1/en active Active
- 2018-11-09 JP JP2019527416A patent/JP6633254B2/ja active Active
- 2018-11-09 WO PCT/US2018/060025 patent/WO2019099298A1/en unknown
- 2018-11-09 ES ES18808599T patent/ES2925219T3/es active Active
- 2018-11-09 US US16/185,801 patent/US10472370B2/en active Active
- 2018-11-09 MY MYPI2020002310A patent/MY197700A/en unknown
- 2018-11-09 HU HUE18808599A patent/HUE060078T2/hu unknown
- 2018-11-09 RS RS20220824A patent/RS63530B1/sr unknown
- 2018-11-09 SG SG11202003677UA patent/SG11202003677UA/en unknown
- 2018-11-09 MD MDE20200963T patent/MD3710446T2/ro unknown
- 2018-11-09 SI SI201830727T patent/SI3710446T1/sl unknown
- 2018-11-09 CR CR20200184A patent/CR20200184A/es unknown
- 2018-11-09 CN CN201880071902.0A patent/CN111344292B/zh active Active
- 2018-11-09 DK DK18808599.7T patent/DK3710446T3/da active
- 2018-11-09 JO JOP/2020/0122A patent/JOP20200122B1/ar active
-
2019
- 2019-09-26 US US16/583,661 patent/US10787460B2/en active Active
-
2020
- 2020-05-07 CL CL2020001218A patent/CL2020001218A1/es unknown
- 2020-05-08 IL IL274540A patent/IL274540B/en unknown
- 2020-05-15 EC ECSENADI202025899A patent/ECSP20025899A/es unknown
- 2020-05-16 SA SA520411990A patent/SA520411990B1/ar unknown
- 2020-06-01 DO DO2020000102A patent/DOP2020000102A/es unknown
- 2020-09-22 US US17/028,334 patent/US20210032257A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221152T1 (hr) | Spojevi korisni u inhibiranju cdk7 | |
| CN104119350B (zh) | 氨基喹唑啉类衍生物及其盐和使用方法 | |
| JP7085985B2 (ja) | 悪性腫瘍治療用製剤及び組成物 | |
| US11446309B2 (en) | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors | |
| CN101678029B (zh) | 基于嘌呤的cdk抑制剂与酪氨酸激酶抑制剂的组合及其在治疗增生性疾病中的用途 | |
| KR101668931B1 (ko) | 항종양제의 효과 증강제 | |
| CN103874689B (zh) | Akt抑制剂化合物和威罗菲尼的组合及使用方法 | |
| ES2744377T3 (es) | Derivado de rapamicina para tratar cáncer de páncreas | |
| CN107427511A (zh) | 包含n‑(3,5‑二甲氧基苯基)‑n’‑(1‑甲基乙基)‑n‑[3‑(1‑甲基‑1h‑吡唑‑4‑基)喹喔啉‑6‑基]乙烷‑1,2‑二胺的药物组合物 | |
| JP2016535756A5 (hr) | ||
| KR102539920B1 (ko) | 종양-치료용 약제학적 조성물 | |
| JP2016533379A5 (hr) | ||
| TW201615191A (zh) | 氨氯地平藥物應用於癌症治療 | |
| MX2010012101A (es) | Metodo de tratamiento del cancer usando un inhibidor de cmet y axl y un inhibidor de erbb. | |
| CN103565653A (zh) | 取代的吡唑酮化合物及其使用方法和用途 | |
| US20190070154A1 (en) | New methods of use for an anti-diarrhea agent | |
| KR20170134462A (ko) | Mdm2 저해제와 btk 저해제의 병용 치료법 | |
| KR20150136074A (ko) | 저용량 이리노테칸염산염 수화물을 함유하는 항종양제 | |
| Li et al. | DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo | |
| CN104761507B (zh) | 氨基喹唑啉衍生物及其在药物中的应用 | |
| WO2019120194A1 (zh) | 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途 | |
| JP2008501690A (ja) | がんの治療方法 | |
| CN113336697A (zh) | 一种cdk9抑制化合物及其应用 | |
| CA2944255C (en) | New derivatives of cephalosporin for treating cancer | |
| CN107362166A (zh) | 四氢吡啶并[4,5‑]噻吩并[2,3‑]嘧啶‑4(3)‑酮类化合物在制药中的应用 |